STOCK TITAN

[Form 4] Cardinal Health, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Insider sale by Cardinal Health officer: The Form 4 shows Deborah Weitzman, identified as an officer (CEO, PSS Segment), sold 21,367 common shares on 08/20/2025 at a weighted average price of $150.53 per share (sales ranged $150.22 to $151.00). After the reported dispositions she beneficially owned 53,428 shares. The filing notes the weighted-average price and offers to provide detailed per-trade quantities and prices on request. No derivative transactions or additional acquisitions are reported in this Form 4.

Vendita insider da parte di un dirigente di Cardinal Health: Il Form 4 indica che Deborah Weitzman, identificata come dirigente (CEO, segmento PSS), ha venduto 21.367 azioni ordinarie il 20/08/2025 a un prezzo medio ponderato di 150,53 USD per azione (operazioni tra 150,22 e 151,00 USD). Dopo tali cessioni risultava beneficiaria di 53.428 azioni. La comunicazione riporta il prezzo medio ponderato e offre di fornire, su richiesta, i dettagli delle singole operazioni con quantità e prezzi. Nel Form 4 non sono segnalate transazioni su derivati né acquisti aggiuntivi.

Venta de insider por parte de un directivo de Cardinal Health: El Formulario 4 muestra que Deborah Weitzman, identificada como ejecutiva (CEO, segmento PSS), vendió 21.367 acciones ordinarias el 20/08/2025 a un precio medio ponderado de 150,53 USD por acción (ventas entre 150,22 y 151,00 USD). Tras las disposiciones comunicadas, era beneficiaria de 53.428 acciones. La presentación indica el precio medio ponderado y ofrece proporcionar, a solicitud, las cantidades y precios por operación. En este Form 4 no se informan transacciones con derivados ni adquisiciones adicionales.

Cardinal Health 임원에 의한 내부자 매도: Form 4에는 Deborah Weitzman이 임원(CEO, PSS 부문)으로 식별되어 2025년 8월 20일에 보통주 21,367주를 주당 가중평균가격 150.53달러(거래 범위: 150.22~151.00달러)에 매도한 것으로 기재되어 있습니다. 해당 처분 이후 그녀는 53,428주를 실질적으로 보유하고 있었습니다. 제출서에는 가중평균가격이 명시되어 있으며, 요청 시 거래별 수량과 가격을 자세히 제공하겠다고 되어 있습니다. 이 Form 4에는 파생상품 거래나 추가 취득 보고는 없습니다.

Vente d'initié par un dirigeant de Cardinal Health : Le formulaire 4 indique que Deborah Weitzman, identifiée comme dirigeante (CEO, segment PSS), a vendu 21 367 actions ordinaires le 20/08/2025 au prix moyen pondéré de 150,53 USD par action (ventes comprises entre 150,22 et 151,00 USD). Après ces cessions, elle détenait bénéficiairement 53 428 actions. Le dossier mentionne le prix moyen pondéré et propose de fournir, sur demande, les quantités et prix par transaction. Aucun contrat dérivé ni acquisition supplémentaire n'est déclaré dans ce Formulaire 4.

Insider-Verkauf durch eine Führungskraft von Cardinal Health: Im Formular 4 wird angegeben, dass Deborah Weitzman, als Führungskraft (CEO, PSS-Segment) geführt, am 20.08.2025 insgesamt 21.367 Stammaktien zu einem gewichteten Durchschnittspreis von 150,53 USD je Aktie verkauft hat (Transaktionen zwischen 150,22 und 151,00 USD). Nach den gemeldeten Veräußerungen hielt sie wirtschaftlich 53.428 Aktien. Die Meldung nennt den gewichteten Durchschnittspreis und bietet an, auf Anfrage detaillierte Angaben zu einzelnen Trades mit Stückzahlen und Preisen bereitzustellen. Im Form 4 sind weder Derivattransaktionen noch weitere Käufe gemeldet.

Positive
  • Transparent disclosure of weighted-average sale price and price range with an offer to provide per-trade details on request
  • Compliance with reporting rules via timely Form 4 submission showing the officer's transactions
Negative
  • Insider disposition of 21,367 common shares, reducing beneficial ownership to 53,428 shares
  • Sale at market prices ($150.22–$151.00), which represents a realized reduction in insider equity stake

Insights

TL;DR: Officer sale of 21,367 shares reduces insider stake to 53,428 shares; transaction transparency is intact.

The reported sale is a straightforward insider disposition reported on Form 4. The weighted-average sale price of $150.53 and the disclosed price range provide clear pricing context. There are no reported option exercises or derivative transactions accompanying this filing, so the change reflects a cash sale of common shares rather than conversion activity. Impact on capitalization is likely immaterial absent additional context about total outstanding shares.

TL;DR: Compliance appears proper; the sale reduces an officer's holding but the filing provides required disclosure.

The Form 4 includes the customary explanation that the reported price is a weighted average across multiple trades and commits to supply per-trade details if requested, which meets disclosure expectations. The transaction was reported as a direct disposition and the filer signed (via attorney-in-fact). No information here indicates a planned trading arrangement or 10b5-1 plan on the face of the form.

Vendita insider da parte di un dirigente di Cardinal Health: Il Form 4 indica che Deborah Weitzman, identificata come dirigente (CEO, segmento PSS), ha venduto 21.367 azioni ordinarie il 20/08/2025 a un prezzo medio ponderato di 150,53 USD per azione (operazioni tra 150,22 e 151,00 USD). Dopo tali cessioni risultava beneficiaria di 53.428 azioni. La comunicazione riporta il prezzo medio ponderato e offre di fornire, su richiesta, i dettagli delle singole operazioni con quantità e prezzi. Nel Form 4 non sono segnalate transazioni su derivati né acquisti aggiuntivi.

Venta de insider por parte de un directivo de Cardinal Health: El Formulario 4 muestra que Deborah Weitzman, identificada como ejecutiva (CEO, segmento PSS), vendió 21.367 acciones ordinarias el 20/08/2025 a un precio medio ponderado de 150,53 USD por acción (ventas entre 150,22 y 151,00 USD). Tras las disposiciones comunicadas, era beneficiaria de 53.428 acciones. La presentación indica el precio medio ponderado y ofrece proporcionar, a solicitud, las cantidades y precios por operación. En este Form 4 no se informan transacciones con derivados ni adquisiciones adicionales.

Cardinal Health 임원에 의한 내부자 매도: Form 4에는 Deborah Weitzman이 임원(CEO, PSS 부문)으로 식별되어 2025년 8월 20일에 보통주 21,367주를 주당 가중평균가격 150.53달러(거래 범위: 150.22~151.00달러)에 매도한 것으로 기재되어 있습니다. 해당 처분 이후 그녀는 53,428주를 실질적으로 보유하고 있었습니다. 제출서에는 가중평균가격이 명시되어 있으며, 요청 시 거래별 수량과 가격을 자세히 제공하겠다고 되어 있습니다. 이 Form 4에는 파생상품 거래나 추가 취득 보고는 없습니다.

Vente d'initié par un dirigeant de Cardinal Health : Le formulaire 4 indique que Deborah Weitzman, identifiée comme dirigeante (CEO, segment PSS), a vendu 21 367 actions ordinaires le 20/08/2025 au prix moyen pondéré de 150,53 USD par action (ventes comprises entre 150,22 et 151,00 USD). Après ces cessions, elle détenait bénéficiairement 53 428 actions. Le dossier mentionne le prix moyen pondéré et propose de fournir, sur demande, les quantités et prix par transaction. Aucun contrat dérivé ni acquisition supplémentaire n'est déclaré dans ce Formulaire 4.

Insider-Verkauf durch eine Führungskraft von Cardinal Health: Im Formular 4 wird angegeben, dass Deborah Weitzman, als Führungskraft (CEO, PSS-Segment) geführt, am 20.08.2025 insgesamt 21.367 Stammaktien zu einem gewichteten Durchschnittspreis von 150,53 USD je Aktie verkauft hat (Transaktionen zwischen 150,22 und 151,00 USD). Nach den gemeldeten Veräußerungen hielt sie wirtschaftlich 53.428 Aktien. Die Meldung nennt den gewichteten Durchschnittspreis und bietet an, auf Anfrage detaillierte Angaben zu einzelnen Trades mit Stückzahlen und Preisen bereitzustellen. Im Form 4 sind weder Derivattransaktionen noch weitere Käufe gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WEITZMAN DEBORAH

(Last) (First) (Middle)
7000 CARDINAL PLACE

(Street)
DUBLIN OH 43017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CARDINAL HEALTH INC [ CAH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, PSS Segment
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 08/20/2025 S 21,367 D $150.53(1) 53,428 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.22 to $151.00, inclusive. The reporting person undertakes to provide to Cardinal Health, Inc., any security holder of Cardinal Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
Remarks:
/s/ James E. Barnett, Attorney-in-fact 08/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Cardinal Health (CAH) Form 4 report for Deborah Weitzman?

The Form 4 reports that Deborah Weitzman sold 21,367 common shares on 08/20/2025 at a weighted-average price of $150.53, leaving her with 53,428 shares beneficially owned.

Was the sale executed at a single price or multiple prices?

The filing states the price is a weighted average of multiple transactions, with prices ranging from $150.22 to $151.00.

Does the Form 4 show any option exercises or derivative transactions for CAH?

No. The Form 4 lists only non-derivative common share dispositions and shows no derivative securities acquired or disposed of.

Who signed the Form 4 for the reporting person?

The Form 4 is signed by James E. Barnett, Attorney-in-fact for the reporting person on the report.

Is there an indication the sale was part of a 10b5-1 trading plan?

The form does not indicate that the transaction was made pursuant to a 10b5-1 plan; no such plan reference appears in the reported fields.
Cardinal Health Inc

NYSE:CAH

CAH Rankings

CAH Latest News

CAH Latest SEC Filings

CAH Stock Data

35.75B
237.56M
0.47%
88.98%
2.34%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
DUBLIN